Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 567Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 7Cipralex/Lexapro

02 6Lexapro

PharmaCompass

01

Brand Name : Cipralex/Lexapro

Escitalopram

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Cipralex/Lexapro

arrow
2024 ACI Convention
Not Confirmed

Escitalopram

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 387

2019 Revenue in Millions : 376

Growth (%) : 3

blank

02

Brand Name : Lexapro

Escitalopram Oxalate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Lexapro

arrow
2024 ACI Convention
Not Confirmed

Escitalopram Oxalate

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 139

2019 Revenue in Millions : 137

Growth (%) : 1

blank

03

Brand Name : Lexapro

Escitalopram Oxalate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Lexapro

arrow
2024 ACI Convention
Not Confirmed

Escitalopram Oxalate

Main Therapeutic Indication : Neurology

Currency : USD

2021 Revenue in Millions : 130

2020 Revenue in Millions : 137

Growth (%) : 2

blank

04

Brand Name : Cipralex/Lexapro

Escitalopram

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Cipralex/Lexapro

arrow
2024 ACI Convention
Not Confirmed

Escitalopram

Main Therapeutic Indication : Neurology

Currency : USD

2021 Revenue in Millions : 358

2020 Revenue in Millions : 381

Growth (%) : -1

blank

05

Brand Name : Cipralex/Lexapro

Escitalopram

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Cipralex/Lexapro

arrow
2024 ACI Convention
Not Confirmed

Escitalopram

Main Therapeutic Indication : Neurology

Currency : USD

2022 Revenue in Millions : 340

2021 Revenue in Millions : 358

Growth (%) : -5

blank

06

Brand Name : Lexapro

Escitalopram Oxalate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Lexapro

arrow
2024 ACI Convention
Not Confirmed

Escitalopram Oxalate

Main Therapeutic Indication : Neurology

Currency : USD

2022 Revenue in Millions : 89

2021 Revenue in Millions : 130

Growth (%) : -31

blank

07

Brand Name : Cipralex/Lexapro

Escitalopram

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Cipralex/Lexapro

arrow
2024 ACI Convention
Not Confirmed

Escitalopram

Main Therapeutic Indication : Neurology

Currency : USD

2023 Revenue in Millions : 308

2022 Revenue in Millions : 340

Growth (%) : -10

blank

08

Brand Name : Lexapro

Escitalopram Oxalate

arrow
2024 ACI Convention
Not Confirmed

09

Brand Name : Cipralex/Lexapro

Escitalopram Oxalate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Cipralex/Lexapro

arrow
2024 ACI Convention
Not Confirmed

Escitalopram Oxalate

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2017 Revenue in Millions : 403

2016 Revenue in Millions : 428

Growth (%) : -6

blank

10

Brand Name : Cipralex/Lexapro

Escitalopram Oxalate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Cipralex/Lexapro

arrow
2024 ACI Convention
Not Confirmed

Escitalopram Oxalate

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2018 Revenue in Millions : 339

2017 Revenue in Millions : 359

Growth (%) : -6%

blank